49 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Cmpds
Data
Article Title
Organization
1
Synthesis, characterization and antitubercular activities of novel pyrrolyl hydrazones and their Cu-complexes.
S.E.T'S College of Pharmacy
25
Piperazine derivatives: synthesis, inhibition of the Mycobacterium tuberculosis enoyl-acyl carrier protein reductase and SAR studies.
Pontif£Cia Universidade Cat£Lica Do Rio Grande Do Sul
8
Development of benzo[d]oxazol-2(3H)-ones derivatives as novel inhibitors of Mycobacterium tuberculosis InhA.
Birla Institute of Technology
2
Diarylthiazole: an antimycobacterial scaffold potentially targeting PrrB-PrrA two-component system.
AstraZeneca
3
2-Phenylindole and Arylsulphonamide: Novel Scaffolds Bactericidal against Mycobacterium tuberculosis.
AstraZeneca
16
Development of 2-(4-oxoquinazolin-3(4H)-yl)acetamide derivatives as novel enoyl-acyl carrier protein reductase (InhA) inhibitors for the treatment of tuberculosis.
Birla Institute of Technology
56
Encoded library technology as a source of hits for the discovery and lead optimization of a potent and selective class of bactericidal direct inhibitors of Mycobacterium tuberculosis InhA.
Glaxosmithkline
14
Methyl-thiazoles: a novel mode of inhibition with the potential to develop novel inhibitors targeting InhA in Mycobacterium tuberculosis.
AstraZeneca
11
3-substituted indole inhibitors against Francisella tularensis FabI identified by structure-based virtual screening.
Naval Research Laboratories
3
Identification of novel antimycobacterial chemical agents through the in silico multi-conformational structure-based drug screening of a large-scale chemical library.
Kyushu Institute of Technology
1
Structural and enzymatic analyses reveal the binding mode of a novel series of Francisella tularensis enoyl reductase (FabI) inhibitors.
University of Illinois At Chicago
1
Chemical synthesis and biological evaluation of triazole derivatives as inhibitors of InhA and antituberculosis agents.
Cnrs
25
Synthesis and in vitro antimycobacterial activity of B-ring modified diaryl ether InhA inhibitors.
Stony Brook University
1
2-Hexadecynoic acid inhibits plasmodial FAS-II enzymes and arrests erythrocytic and liver stage Plasmodium infections.
University of London
30
Discovery of potential new InhA direct inhibitors based on pharmacophore and 3D-QSAR analysis followed by in silico screening.
China Pharmaceutical University
1
Natural products, small molecules, and genetics in tuberculosis drug development.
National Institute of Diabetes and Digestive and Kidney Diseases
2
Agonodepsides a and B: two new depsides from a filamentous fungus F7524.
Institute of Molecular and Cell Biology
16
Discovery of new diaryl ether inhibitors against Mycobacterium tuberculosis targeting the minor portal of InhA.
Universita Toulouse III - Paul Sabatier (UT3)
31
Novel 4-aminoquinolines: Synthesis, inhibition of the Mycobacterium tuberculosis enoyl-acyl carrier protein reductase, antitubercular activity, SAR, and preclinical evaluation.
Pontifical Catholic University of Rio Grande Do Sul
1
Synthesis of 4-phenoxybenzamide adenine dinucleotide as NAD analogue with inhibitory activity against enoyl-ACP reductase (InhA) of Mycobacterium tuberculosis.
University of Minnesota
7
Comprehensive coverage on anti-mycobacterial endeavour reported during 2022.
L. M. College of Pharmacy
2
Drug discovery in tuberculosis. New drug targets and antimycobacterial agents.
Universidade De Lisboa
43
FabI (enoyl acyl carrier protein reductase) - A potential broad spectrum therapeutic target and its inhibitors.
National Institute of Pharmaceutical Education and Research (NIPER)
1
An appraisal of anti-mycobacterial activity with structure-activity relationship of piperazine and its analogues: A review.
University of Kwazulu-Natal (Westville)
36
Fragment-to-Lead Medicinal Chemistry Publications in 2020.
Vrije Universiteit Amsterdam
10
Boron-Containing heterocycles as promising pharmacological agents.
Long Island University
1
Antitubercular properties of thiazolidin-4-ones - A review.
Medical University of Lublin
2
Design and synthesis of thiourea-based derivatives as Mycobacterium tuberculosis growth and enoyl acyl carrier protein reductase (InhA) inhibitors.
Erciyes University
1
Exploring the chemical space of 1,2,3-triazolyl triclosan analogs for discovery of new antileishmanial chemotherapeutic agents.
Instituto De Qu£Mica Rosario
26
Discovery and development of novel rhodanine derivatives targeting enoyl-acyl carrier protein reductase.
Nanjing University
1
Discovery of novel N-methyl carbazole tethered rhodanine derivatives as direct inhibitors of Mycobacterium tuberculosis InhA.
University of Kwazulu-Natal (Ukzn)
8
Synthesis and Structure-Activity Relationship Studies of C2-Modified Analogs of the Antimycobacterial Natural Product Pyridomycin.
Eth Zurich
2
Synthesis and antimycobacterial activity of 2,1'-dihydropyridomycins.
Swiss Federal Institute of Technology (Eth) Zurich
34
An overview on crystal structures of InhA protein: Apo-form, in complex with its natural ligands and inhibitors.
Cnrs
2
Recent advances of pyrazole-containing derivatives as anti-tubercular agents.
Wuhan University of Science and Technology
3
Discovery of novel anti-tuberculosis agents with pyrrolo[1,2-a]quinoxaline-based scaffold.
West China Hospital
7
STEROID COMPOUND, AND PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF
Jiangsu Simcere Pharmaceutical
119
Compounds and their administration for treating a neurodegenerative disease as well as a method for identifying a compound capable of inhibiting a kinase, such as LRRK
Medical Research Council Technology
2
Anxiolytic- and antidepressant-like profile of ATC0065 and ATC0175: nonpeptidic and orally active melanin-concentrating hormone receptor 1 antagonists.
Taisho Pharmaceutical
8
Evaluation of short-tether bis-THA AChE inhibitors. A further test of the dual binding site hypothesis.
Hong Kong University of Science and Technology